ANI Pharmaceuticals reports Q2 adjusted EPS $1.02, consensus 95c

Reports Q2 revenue $138.0M, consensus $129.05M. “We are very proud of our accomplishments in Q2. We delivered both record revenues and a major milestone in our ongoing efforts to expand the scope and scale of our Rare Disease business with the proposed acquisition of Alimera,” said CEO Nikhil Lalwani. “…Based on our solid Q2 results and the continued momentum we’re seeing across the business, we are raising our full year 2024 guidance. Following the acquisition of Alimera, ANI will have three growing and durable commercial Rare Disease assets, an expanded commercial team covering five specialties, and a global infrastructure covering over 20 countries. We’re pleased with our progress thus far in 2024 and are excited about the opportunities that lie ahead, as we make further strides in our mission of ‘Serving Patients, Improving Lives'”.